A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell Disease

About the study

This is a phase 1, first-in-human, multi-center, open-label, single dose cohort study to evaluate the safety and tolerability, pharmacokinetics (PK), exploratory pharmacodynamics (PD), and biomarkers of target engagement of CSL889 following single intravenous (IV) doses in subjects with sickle cell disease (SCD). The study involves sequential dose escalation of cohorts with between-group assessments of key safety and PK variables.

Study point of contact

Trial Registration Coordinator
[email protected]


4 United States sites

4 United Kingdom sites

1 Netherlands site


18 to 60 Years




Phase 1

Study type



18 Years - 60 Years







participation requirements

Diagnosis of SCD characterized by HbSS or SCD characterized by the compound heterozygous state of the βS mutation with β0 thalassemia mutations (HbSβ0)
Aged 18 to 60 years, inclusive
Stable SCD for at least 30 days before CSL889 infusion (Part A) or subject hospitalized for uncomplicated VOC (Part B)
Subject is either not taking hydroxyurea and / or L-glutamine, or subject has been taking hydroxyurea and / or L-glutamine for at least 30 days before Day 1 on a stable, well tolerated regimen that is planned to continue without change throughout the study

participation restrictions

History of primary hemorrhagic stroke
History or evidence of inherited bleeding diathesis or significant coagulopathy at risk for bleeding
Weight >110 kg (242 lbs)
Surgery within 30 days before Day 1 or any preplanned surgeries during the study (minor surgeries may be permitted under local anesthesia before screening, with permission of the medical monitor)
Female subjects who are pregnant or breastfeeding
Female subject of childbearing potential or fertile male subject either not using or not willing to use an acceptable method of contraception to avoid pregnancy during the study and for 30 days after receipt of CSL889.
Treatment with any other drug / biologic that is newly approved for SCD during the conduct of this study within 90 days before Day 1.
Treatment with another investigational product within 30 days or within 5 half-lives of the product (whichever is greater) before Day 1
Vaccination within 30 days before Day 1, or planned vaccination during the study
Body-mass index < 16 kg/m2 or weight < 50 kg (110 lbs) History of anaphylactic-type reactions, transfusion related reaction, asthma, or autoimmune disease


  • Chicago, Illinois, United States, University of Illinois Hospital and Health Science Systems, 60612 [Recruiting]
  • Minneapolis, Minnesota, United States, University of Minnesota, 55455 [Recruiting]
  • Columbus, Ohio, United States, Ohio State University, 43201 [Recruiting]
  • Charleston, South Carolina, United States, Medical University of South Carolina, 29425 [Recruiting]
  • Amsterdam, Netherlands, Amsterdam UMC Academic Medical Center [Recruiting]
  • Liverpool, United Kingdom, Liverpool University Hospital [Recruiting]
  • London, United Kingdom, Guys and St. Thomas [Recruiting]
  • London, United Kingdom, University College London Hospital [Recruiting]
  • Manchester, United Kingdom, Early Phase Unit [Recruiting]
Last updated 2022-03-30